Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel
Autor: | Arjen Nikkels, Andrée Rorive, Nathalie Marchal, Eve Lebas |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Skin Neoplasms Cutaneous squamous cell carcinoma Programmed Cell Death 1 Receptor Locally advanced Pembrolizumab Antibodies Monoclonal Humanized 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Programmed cell death 1 Humans Medicine Pharmacology (medical) biology business.industry Prognosis Position (obstetrics) 030104 developmental biology Oncology 030220 oncology & carcinogenesis Carcinoma Squamous Cell biology.protein Cancer research business Solid organ transplantation |
Zdroj: | Expert Review of Anticancer Therapy. 21:355-363 |
ISSN: | 1744-8328 1473-7140 |
Popis: | Locally advanced cutaneous squamous cell carcinoma (lacSCC) is rare. Approximately one-fourth of the cases are observed among immunocompromised patients, in particular in solid organ transplant recipients (OTRs). LacSCC has a very poor prognosis. Surgery with or without radiotherapy remains the golden standard of treatment for cSCC. However, in advanced cases, there is a medical need for alternative treatment options. Classic systemic treatments include chemotherapy and/or EGFR inhibitors. Recently the effectiveness of programmed cell death protein-1 (PD-1) inhibitors has been demonstrated for lacSCC. Cemiplimab is a recombinant IgG4 human monoclonal antibody against the PD-1 protein for the intravenous treatment of lacSCC.The principal studies evaluating the efficacy and safety of cemiplimab for lacSCC are presented.Cemiplimab is the first anti-PD-1 antibody that was FDA (2018) and EMA (2019) approved as a systemic treatment for lacSCC and/or metastatic cSCC when curative surgery or radiotherapy is no longer amenable. For this situation, experts currently recommend cemiplimab as a first-line systemic alternative. As cemiplimab therapy is potentially associated with a risk of organ graft rejection, pros and cons should be evaluated for every individual OTR patient with lacSCC. |
Databáze: | OpenAIRE |
Externí odkaz: |